Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

被引:192
作者
White, Ann L. [1 ]
Chan, H. T. Claude [1 ]
Roghanian, Ali [1 ]
French, Ruth R. [1 ]
Mockridge, C. Ian [1 ]
Tutt, Alison L. [1 ]
Dixon, Sandra V. [1 ]
Ajona, Daniel [1 ]
Verbeek, J. Sjef [2 ]
Al-Shamkhani, Aymen [1 ]
Cragg, Mark S. [1 ]
Beers, Stephen A. [1 ]
Glennie, Martin J. [1 ]
机构
[1] Univ Southampton, Fac Med, Div Canc Sci, Southampton SO16 6YD, Hants, England
[2] Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands
关键词
C-RECEPTOR POLYMORPHISMS; T-CELL TOLERANCE; IN-VIVO; CD20; IMMUNOTHERAPY; CD40; PATHWAY; B-CELLS; LYMPHOMA; CANCER; THERAPY; TUMOR;
D O I
10.4049/jimmunol.1101135
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A high activatory/inhibitory Fc gamma R binding ratio is critical for the activity of mAb such as rituximab and alemtuzumab that attack cancer cells directly and eliminate them by recruiting immune effectors. Optimal Fc gamma R binding profiles of other anti-cancer mAb, such as immunostimulatory mAb that stimulate or block immune receptors, are less clear. In this study, we analyzed the importance of isotype and Fc gamma R interactions in controlling the agonistic activity of the anti-mouse CD40 mAb 3/23. Mouse IgG1 (m1) and IgG2a (m2a) variants of the parental 3/23 (rat IgG2a) were engineered and used to promote humoral and cellular responses against OVA. The mouse IgG1 3/23 was highly agonistic and outperformed the parental Ab when promoting Ab (10-100-fold) and T cell (OTI and OTII) responses (2- to >10-fold). In contrast, m2a was almost completely inactive. Studies in Fc gamma R knockout mice demonstrated a critical role for the inhibitory Fc gamma RIIB in 3/23 activity, whereas activatory Fc gamma R (Fc gamma RI, -III, and -IV) was dispensable. In vitro experiments established that the stimulatory effect of Fc gamma RIIB was mediated through Ab cross-linking delivered in trans between neighboring cells and did not require intracellular signaling. Intriguingly, activatory Fc gamma R provided effective cross-linking of 3/23 m2a in vitro, suggesting the critical role of Fc gamma RIIB in vivo reflects its cellular distribution and bioavailability as much as its affinity for a particular Ab isotype. In conclusion, we demonstrate an essential cross-linking role for the inhibitory Fc gamma RIIB in anti-CD40 immunostimulatory activity and suggest that isotype will be an important issue when optimizing reagents for clinical use. The Journal of Immunology, 2011, 187: 1754-1763.
引用
收藏
页码:1754 / 1763
页数:10
相关论文
共 50 条
[21]   Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity [J].
Knorr, David A. ;
Dahan, Rony ;
Ravetch, Jeffrey, V .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (43) :11048-11053
[22]   Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment [J].
Zippelius, Alfred ;
Schreiner, Jens ;
Herzig, Petra ;
Mueller, Philipp .
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (03) :236-244
[23]   CD40 signaling activated by agonistic anti-CD40 monoclonal antibody 5C11 has different effects on biological behavior of gastric carcinoma cells [J].
Li Rui ;
Chen Wei-Chang ;
Wang Wei-peng ;
Tian Wen-yan ;
Zhang Xue-guang .
IMMUNOLOGY LETTERS, 2010, 131 (02) :120-125
[24]   A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma [J].
Hussein, Mohamad ;
Berenson, James R. ;
Niesvizky, Ruben ;
Munshi, Nikhil ;
Matous, Jeffrey ;
Sobecks, Ronald ;
Harrop, Kate ;
Drachman, Jonathan G. ;
Whiting, Nancy .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (05) :845-848
[25]   Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo [J].
Li, Fubin ;
Ravetch, Jeffrey V. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (48) :19501-19506
[26]   Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo [J].
Roghanian, Ali ;
Teige, Ingrid ;
Martensson, Linda ;
Cox, Kerry L. ;
Kovacek, Mathilda ;
Ljungars, Anne ;
Mattson, Jenny ;
Sundberg, Annika ;
Vaughan, Andrew T. ;
Shah, Vallari ;
Smyth, Neil R. ;
Sheth, Bhavwanti ;
Chan, H. T. Claude ;
Li, Zhan-Chun ;
Williams, Emily L. ;
Manfredi, Giusi ;
Oldham, Robert J. ;
Mockridge, C. Ian ;
James, Sonya A. ;
Dahal, Lekh N. ;
Hussain, Khiyam ;
Nilsson, Bjorn ;
Verbeek, J. Sjef ;
Juliusson, Gunnar ;
Hansson, Markus ;
Jerkeman, Mats ;
Johnson, Peter W. M. ;
Davies, Andrew ;
Beers, Stephen A. ;
Glennie, Martin J. ;
Frendeus, Bjorn ;
Cragg, Mark S. .
CANCER CELL, 2015, 27 (04) :473-488
[27]   Agonistic anti-CD40 therapy synergizes with LAG-3-blocking antibodies [J].
Mueller, Philipp ;
Thommen, Daniela S. ;
Zippelius, Alfred .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (08) :692-694
[28]   Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies [J].
Li, Da-Ke ;
Wang, Wen .
ONCOLOGY LETTERS, 2020, 20 (05)
[29]   Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells [J].
T S Lewis ;
R S McCormick ;
I J Stone ;
K Emmerton ;
B Mbow ;
J Miyamoto ;
J G Drachman ;
I S Grewal ;
C-L Law .
Leukemia, 2011, 25 :1007-1016
[30]   Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells [J].
Lewis, T. S. ;
McCormick, R. S. ;
Stone, I. J. ;
Emmerton, K. ;
Mbow, B. ;
Miyamoto, J. ;
Drachman, J. G. ;
Grewal, I. S. ;
Law, C-L .
LEUKEMIA, 2011, 25 (06) :1007-1016